Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 3/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20088227 | 0.89 | HRH3 (0.36) | HRH3KCNH2CYP2D6PARP1PARP2 | |
| SCHEMBL12095083 | 0.89 | HRH3 (0.36) | HRH3KCNH2CYP2D6PARP1PARP2 | |
| SCHEMBL14725147 | 0.82 | HRH3 (0.41) | HRH3KCNH2CYP2D6ALDH1A1HTR4 | |
| SCHEMBL1261174 | 0.82 | HRH3 (0.44) | HRH3KCNH2CYP2D6ALDH1A1ITGB3 | |
| SCHEMBL10331809 | 0.81 | HRH3 (0.40) | HRH3KCNH2CYP2D6ALDH1A1HTR4 | |
| Hydrochloric Acid SCHEMBL2942000 | 0.81 | HRH3 (0.43) | HRH3KCNH2CYP2D6ALDH1A1ITGB3 | |
| SCHEMBL13999390 | 0.80 | HRH3 (0.39) | HRH3KCNH2CYP2D6ALDH1A1HTR4 | |
| SCHEMBL3317297 | 0.79 | CCR2 (0.40) | KCNH2CYP2D6PARP1PARP2 | |
| SCHEMBL3319700 | 0.79 | CCR2 (0.40) | KCNH2CYP2D6PARP1PARP2 | |
| SCHEMBL3316372 | 0.79 | CCR2 (0.40) | KCNH2CYP2D6PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2024-02-29 | — | — | US | disclosed |
| WO-2023233033-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2023-12-07 | — | — | WO | disclosed |
| CN-108699032-B | Polycyclic TLR7/8 antagonists and their use in the treatment of immune disorders | 默克专利有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | GI Therapeutics, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| WO-2020025517-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-02-06 | — | — | WO | disclosed |
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190119294-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10183944-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ASANA BIOSCIENCES, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | ASANA BIOSCIENCES, LLC (US) | 2017-06-08 | — | — | US | disclosed |
| US-8729079-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ENDO PHARMACEUTICALS INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ENDO PHARMACEUTICALS INC (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183944-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | THPO, TYMP, TYMS | HRH3 866/4885KCNH2 2093/4885CYP2D6 133/4885 |
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | HRH3 3742/4885KCNH2 4779/4885CYP2D6 3417/4885 |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | MKI67, DPYD, PCNA | HRH3 3893/4885KCNH2 4395/4885CYP2D6 2542/4885 |
| US-20190119294-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | TYMS, TYMP, DPYD | HRH3 3572/4885KCNH2 4712/4885CYP2D6 2612/4885 |
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | MKI67, DPYD, TYMP | HRH3 2015/4885KCNH2 2545/4885CYP2D6 419/4885 |
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | HRH3 586/4885KCNH2 2460/4885CYP2D6 847/4885 |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | HRH3 866/4885KCNH2 2093/4885CYP2D6 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.